**Supplementary Table S2. Clinicopathologic characteristics of patients with pancreatic cancer in the validation cohort**

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | High expression of DPYSL3 in PDAC pts. | Low expression of DPYSL3 in PDAC pts. | P value |
| All patients | 8 | 14 |  |
| Age (y.o) |
|  ≤ 70  | 2 | 9 | 0.183 |
|  > 70  | 6 | 5 |
| Sex |
|  Male | 5 | 9 | 1.000 |
|  Female | 3 | 5 |
| pT# status |
|  Tis/1 | 0 | 0 | 0.649 |
|  T2 | 0 | 0 |
|  T3 | 6 | 8 |
|  T4 | 2 | 6 |
| pN# status\* |
|  N0 | 1 | 7 | 0.167 |
|  N1 | 7 | 7 |
| pStage# status |
| 0 / I | 0 | 0 | 0.158 |
|  II | 0 | 2 |
|  III | 7 | 6 |
|  IVa | 1 | 6 |
| IVb | 0 | 0 |

#pT = pathologic primary tumor; pN = pathologic lymph node status; pStage = pathologic disease stage.

\*, p = 0.046 as determined by Fisher’s exact test.